


This listing of claims will replace all prior versions of claims in the application.

Claims 1-18. (cancelled)

Claim 19. (new) A compound of the following general formula:



wherein:

A represents an optionally substituted 5- or 6-membered heteroaryl ring

X is O, S or a group of Formula NR<sup>13</sup> or CR<sup>14</sup>R<sup>15</sup>;


Y is O, S or a group of Formula NR<sup>16</sup> and

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup> and R<sup>16</sup> are independently of each other H, alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, heterocycloalkyl, aralkyl or heteroaralkyl,

or two of R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup> and R<sup>16</sup> constitute part of a cycloalkyl or heterocycloalkyl;

or a pharmacologically acceptable salt, solvate, hydrate or a pharmacologically acceptable formulation thereof.


wherein compounds of Formula (I) are excluded,



wherein R' is H, alkyl, alkenyl, aryl, or heteroaryl, and R'' is H, OH, alkyl, aryl or heteroaryl.

Claim 20. (new) A compound of claim 19, wherein A has the following structure:

Rule  
1.126



Claim 21. (new) A compound of claim 19 wherein X is a CH<sub>2</sub> group.

22.

Claim 23. (new) A compound of claim 19 wherein Y is O.

23.

Claim 24. (new) A compound of claim 19 wherein R<sup>1</sup> is C<sub>1</sub>-C<sub>4</sub> alkyl.

24.

Claim 25. (new) A compound of claim 19 wherein R<sup>2</sup> and R<sup>3</sup> together constitute a group of Formula (CH<sub>2</sub>)<sub>n</sub> wherein n is 2, 3, 4 or 5.

25.

Claim 26. (new) A compound of claim 19 wherein R<sup>4</sup> is H or methyl.

26.

Claim 27. (new) A compound of claim 19 wherein R<sup>5</sup> is H.

27.

Claim 28. (new) A compound of claim 19 wherein R<sup>6</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl or C<sub>4</sub>-C<sub>7</sub> alkylcycloalkyl.

1.126  
28.

Claim 29. (new) A compound of claim 19 wherein R<sup>7</sup> is H or methyl.

29.

Claim 30. (new) A compound of claim 19 wherein R<sup>8</sup> is a group of Formula CH<sub>2</sub>OCOR<sup>17</sup>, wherein R<sup>17</sup> is C<sub>1</sub>-C<sub>7</sub> alkyl or C<sub>1</sub>-C<sub>6</sub> alkenyl.

30.

Claim 31. (new) A compound of claim 19 wherein R<sup>9</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl.

31.

Claim 32. (new) A compound of claim 19 wherein R<sup>10</sup> is H or methyl.

32.

Claim 33. (new) A compound of claim 19 wherein R<sup>11</sup> is H or a group of Formula (C=O)-(C<sub>1</sub>-<sub>4</sub>)alkyl.

33.

Claim 34. (new) A compound of claim 19 wherein R<sup>12</sup> is a group of Formula NR<sup>18</sup>R<sup>19</sup>, wherein R<sup>18</sup> is H or methyl and R<sup>19</sup> is aralkyl or heteroaralkyl.

34.

Claim 35. (new) A pharmaceutical composition comprising a compound of claim 19 and optionally one or more carriers and/or adjuvants.

35.

Claim 36. (new) A method for treating a patient suffering from or susceptible to a tumor, immune disease, autoimmune disease, inflammatory disease or rheumatoid arthritis, comprising administering to the patient one or more compounds of claim 19.

36.

Claim 37. (new) The method of claim 36 wherein the patient is identified as suffering from a tumor, immune disease, autoimmune disease, inflammatory disease or rheumatoid arthritis, and the one or more compounds are administered to the identified patient.

Rule  
1.126

37.

**Claim 38.** (new) A method for treating a patient suffering from cancer, comprising administering to the patient one or more compounds of claim 19.

38.

**Claim 39.** (new) The method of claim 38 wherein the patient is identified as suffering from cancer and the one or more compounds are administered to the identified patient.